Compare ALDX & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALDX | SACH |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 40.6M |
| IPO Year | 2014 | 2016 |
| Metric | ALDX | SACH |
|---|---|---|
| Price | $0.63 | $0.69 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 857.2K | 116.4K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 5.71% |
| EPS Growth | 40.43 | ★ 104.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $57,500,000.00 |
| Revenue This Year | N/A | $94.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $0.69 |
| 52 Week High | $5.93 | $1.45 |
| Indicator | ALDX | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 17.03 |
| Support Level | $0.53 | N/A |
| Resistance Level | $1.58 | $0.87 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 59.09 | 4.31 |
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.